About
Overview
Management team
Board of directors
Investors
Scientific advisory board
Innovation
Overview
Pipeline
Technology
Usher 1B
Stargardt
Clinical trials
Overview
LUCE-1
STELLA
CELESTE
For patients
Overview
About IRDs
AAV Gene Therapy in Inherited Retinal Diseases (IRDs)
What is Usher Syndrome Type 1B (Usher 1B)?
What is Stargardt disease?
About clinical trials
FAQs
Patient resources
Expanded access
Explore our videos
News
Careers
Overview
Corporate values
Recruitment companies
Contact
EN
English
Italiano
Search
News
News
Filter by:
All categories
All categories
Press Release
Publication
All disease areas
All disease areas
Stargardt
Usher 1B
Other
By year:
All years
All years
2026
2025
2024
2023
2022
2021
2019
2014
Reset
23.07.2026
Press Release
Other
AAVantgarde Announces Participation of Founder and CSO, Prof. Alberto Auricchio at the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy
23.04.2026
Press Release
Usher 1B
AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study
21.04.2026
Press Release
Stargardt
AAVantgarde announces completion of recruitment in STELLA natural history study
01.04.2026
Press Release
Other
AAVantgarde appoints Philip Lao as Senior Vice President Business Development
15.01.2026
Press Release
Usher 1B
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
08.01.2026
Press Release
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference